The tesamorelin carpal tunnel warning has a straightforward explanation: extra fluid can press on a nerve in the wrist. Carpal tunnel syndrome means that nerve is squeezed where it passes through a narrow wrist passage. Tingling, numbness, and pain can follow.
That is one possible cause, not a diagnosis from a symptom alone. Other health conditions and pressure on nerves elsewhere can also matter. Egrifta WR's patient information tells people to call their healthcare provider about pain or numbness in the hands or wrist, even when swelling looks mild.
Why tesamorelin carpal tunnel symptoms can happen
Tesamorelin prompts the pituitary, a small gland beneath the brain, to release growth hormone, which helps regulate growth and fuel use. It also raises IGF-1, a growth signal made mainly by the liver. Increased growth-hormone release can make the body retain fluid.
Fluid retention means extra fluid held in body tissues. Around the wrist, swelling can crowd the median nerve, which supplies feeling to the thumb and several fingers. Pressure on that nerve explains why hand tingling can appear alongside swelling and joint discomfort.
Section 5.3 of the Egrifta WR prescribing information specifically names carpal tunnel syndrome among fluid-related problems. It does not mean every episode of tingling has that cause.
WR's safety information draws on the original Egrifta product. The Egrifta label walkthrough explains that distinction. The prescribing information was last revised in March 2025.
A pins-and-needles sensation is not a measure of benefit. The broader tesamorelin side-effects guide covers the other reactions and monitoring issues; the hand symptoms need their own assessment.
What the Egrifta trials actually recorded
The relevant numbers come from the first 26 weeks of two trials combined. There were 543 people receiving tesamorelin and 263 receiving placebo, an inactive comparison treatment. Falutz and colleagues' pooled analysis, published in the Journal of Clinical Endocrinology & Metabolism in 2010, confirms those groups.
The FDA label's Table 1 reports these percentages:
| Recorded reaction | Tesamorelin, 543 people | Placebo, 263 people |
|---|---|---|
| Carpal tunnel syndrome | 1% | 0% |
| Peripheral edema, swelling in the limbs | 6% | 2% |
| Paresthesia, tingling or pins and needles | 5% | 2% |
| Hypoesthesia, reduced sensation | 4% | 2% |
Tingling affected about 1 in 20 treated participants, while carpal tunnel syndrome was recorded less often. That tingling figure is not specific to the hands. The rows describe different reported reactions.
They cannot be added together to calculate a hand-symptom rate, because one person could have more than one reaction. A displayed 0% is not a promise of zero risk.
These studies involved adults with HIV, a virus that weakens immune defenses, and lipodystrophy, a change in fat distribution. The studies primarily measured abdominal fat. These were not trials of otherwise healthy people seeking general body changes.
Hand numbness has more than one possible cause
Carpal tunnel symptoms often involve the thumb, index finger, middle finger, and part of the ring finger. They may wake someone at night. Weakness or dropping objects can appear too, as the American Academy of Orthopaedic Surgeons explains.
Diabetes, a condition involving high blood sugar, can increase the likelihood of carpal tunnel syndrome. So can problems with the thyroid, a neck gland that helps control how the body uses energy. Rheumatoid arthritis, a disease causing joint inflammation, is another risk factor. These deserve attention even when symptoms began after tesamorelin.
Pressure on a nerve in the neck or elsewhere in the arm can produce a different pattern of numbness.
The timing is useful evidence, but it cannot settle the diagnosis. A clinician compares which fingers are affected, whether one or both hands are involved, and whether feeling or strength is changing. Wrist pain by itself is not proof of a compressed nerve.
What a prescriber checks when hands start tingling
A review starts with the symptom pattern and its timing relative to treatment. The clinician examines sensation, grip, and thumb strength, and checks for swelling. Current medicines, other hormone treatments, diabetes, and thyroid history help fill in the picture.
Blood sugar and IGF-1 may also need review under the tesamorelin monitoring plan. Those blood tests answer different questions from a hand examination. An IGF-1 result cannot diagnose carpal tunnel syndrome.
As of November 5, 2026, the day this article was written, a guideline synopsis published November 2, 2026 emphasizes symptoms and examination as the basis of diagnosis. Electrical nerve tests measure how well nerves carry signals; ultrasound uses sound waves to make images. The synopsis explains that these tests can help when the diagnosis is uncertain, rather than being routine for everyone. It summarizes the existing 2024 orthopedic guideline; it is not a new tesamorelin safety trial.
For the wider visit discussion, questions to ask before tesamorelin covers medical history and monitoring. New hand symptoms make that an ongoing conversation, not just an intake question.
Does the numbness go away?
The label describes fluid-related reactions as temporary or resolving after treatment is stopped. That does not set a recovery deadline for every numb hand. Pressure on the wrist nerve that goes on too long can cause lasting damage, which is why the label's patient information asks people to call their healthcare provider about any pain or numbness in the hands or wrist, not only when sensation or grip gets worse.
The prescriber decides whether treatment needs changing or stopping. The actual dose and follow-up plan belong with that clinician. A symptom report gives them a reason to reassess, rather than a formula for adjusting treatment at home.
Breathing trouble or swelling of the face or throat can signal a serious allergic reaction and requires emergency medical care. Milder allergic reactions such as rash, hives, itching or flushing occurred in 4% of trial participants; the label advises prompt medical attention and stopping treatment if one is suspected. That is a different problem from routine wrist tingling.
What a prescribed formulation changes
A prescribed route identifies the accountable clinician, the licensed U.S. pharmacy dispensing the medication, and a contact for reporting side effects. Pharmacy records also allow a production batch to be traced. Those details matter when symptoms need follow-up.
Compounding means a pharmacy prepares a medication for an individual prescription. Tesamorelin prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Egrifta WR's labeled use concerns excess abdominal fat in adults with HIV-associated lipodystrophy. Its trial percentages cannot establish identical risks for a compounded preparation.
A licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
